The year of the ox in 2023 brought many uncertainties to the pharma sector in China, but as we move to the year of the dragon in the 12-year Chinese zodiac cycle, the outlook is for multiple further changes in the country's biopharma policy and regulatory environment.
China Regulation in Year Of The Dragon: Good Distribution Practice, Corporate Law, Export Bans
NMPA Raises Distributor Bar
A plethora of new and revised regulations in China to regulate drug distribution and storage, the set up of new corporations, administrative appeals, as well as the export of gene editing technology, are set to come into effect in 2024, ushering in more challenges to pharma and life sciences companies operating in the country.
